IRESSA™ (Gefitinib) in Breast Cancer Patients
Launched by ASTRAZENECA · Mar 4, 2008
Trial Information
Current as of July 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • histological or cytological confirmation of breast cancer that is either
- • a primary tumour in a patient unfit for or who has declined surgery
- • advanced (locally or metastatic) disease
- • acquired resistance to tamoxifen or ER negative tumour
- • at least one measurable or assessable lesion
- • WHO performance status 0 - 2
- • life expectancy of 12 weeks or more
- Exclusion Criteria:
- • more than one previous chemotherapy regimens for advanced disease
- • prior anthracycline chemotherapy (\> 250 mg/m2 adriamycin)
- • radiotherapy completed within 14 days prior to Day 1 of treatment
- • incomplete healing from prior oncologic or other major surgery
- • signs of neurological symptoms consistent with spinal cord compression
- • any evidence of clinically active interstitial lung disease (patients with chronic stable
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
R Robertson, MD
Principal Investigator
City Hospital, Nottingham , UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials